Dr. Brown is a prominent serial entrepreneur in the biotechnology sector with over thirty years of expertise in cancer biology, drug discovery and development. He has served as Director of Rakovina Therapeutics Inc., (TSXV:RKV), Chief Scientific Officer and Director of DelMar Pharmaceuticals (NASDAQ:DMPI) (now Kintara Therapeutics, Inc) and Chairman of the Board of Mountain View Pharmaceuticals.. Dr Brown founded ChemGenex Therapeutics, which merged with a publicly traded Australian company to become ChemGenex Pharmaceuticals (ASX:CXS/NASDAQ:CXSP), of which he served as President and a Director. He was instrumental in the development, FDA approval, and commercialization of Synribo (omacetaxine mepesuccinate), a plant-derived treatment for chronic myeloid leukemia. Previously Dr. Brown co-founded Matrix Pharmaceutical, Inc., where he held the roles of Vice President of Scientific Affairs and VP of Discovery Research. His academic appointments include Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School.